title: Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids.
abstract: In nonalcoholic fatty liver disease, hepatic gene expression and fatty acid (FA) composition have been reported independently, but a comprehensive gene expression profiling in relation to FA composition is lacking. The aim was to assess this relationship. In a cross-sectional study, hepatic gene expression (Illumina Microarray) was first compared among 20 patients with simple steatosis (SS), 19 with nonalcoholic steatohepatitis (NASH), and 24 healthy controls. The FA composition in hepatic total lipids was compared between SS and NASH, and associations between gene expression and FAs were examined. Gene expression differed mainly between healthy controls and patients (SS and NASH), including genes related to unsaturated FA metabolism. Twenty-two genes were differentially expressed between NASH and SS; most of them correlated with disease severity and related more to cancer progression than to lipid metabolism. Biologically active long-chain polyunsaturated FAs (PUFAs; eicosapentaenoic acid + docosahexaenoic acid, arachidonic acid) in hepatic total lipids were lower in NASH than in SS. This may be related to overexpression of FADS1, FADS2, and PNPLA3. The degree and direction of correlations between PUFAs and gene expression were different among SS and NASH, which may suggest that low PUFA content in NASH modulates gene expression in a different way compared with SS or, alternatively, that gene expression influences PUFA content differently depending on disease severity (SS versus NASH).
  
  
  CONCLUSIONS
  Well-defined subjects with either healthy liver, SS, or NASH showed distinct hepatic gene expression profiles including genes involved in unsaturated FA metabolism. In patients with NASH, hepatic PUFAs were lower and associations with gene expression were different compared to SS.
authors.affiliation: Toronto General Hospital, University Health Network, Toronto, ON, Canada.
authors.forename: Bianca M
authors.initials: BM
authors.lastname: Arendt
authors.forename: Elena M
authors.initials: EM
authors.lastname: Comelli
authors.forename: David W L
authors.initials: DW
authors.lastname: Ma
authors.forename: Wendy
authors.initials: W
authors.lastname: Lou
authors.forename: Anastasia
authors.initials: A
authors.lastname: Teterina
authors.forename: TaeHyung
authors.initials: T
authors.lastname: Kim
authors.forename: Scott K
authors.initials: SK
authors.lastname: Fung
authors.forename: David K H
authors.initials: DK
authors.lastname: Wong
authors.forename: Ian
authors.initials: I
authors.lastname: McGilvray
authors.forename: Sandra E
authors.initials: SE
authors.lastname: Fischer
authors.forename: Johane P
authors.initials: JP
authors.lastname: Allard
mesh_terms: D000328:Adult; D003430:Cross-Sectional Studies; D000090943:Delta-5 Fatty Acid Desaturase; D015525:Fatty Acids, Omega-3 / Q000097:blood* / Q000235:genetics*; D043371:Fatty Acids, Omega-6 / Q000097:blood* / Q000235:genetics*; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D008099:Liver / Q000378:metabolism*; D008297:Male; D065626:Non-alcoholic Fatty Liver Disease / Q000235:genetics* / Q000378:metabolism*
chemical_list: D000090943:Delta-5 Fatty Acid Desaturase; D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; C000716847:FADS1 protein, human